These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Kabbara WK; Ramadan WH J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States. Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146 [TBL] [Abstract][Full Text] [Related]
8. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
9. [HIV therapy and adherence]. Kuhlmann B MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920 [No Abstract] [Full Text] [Related]
10. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy. Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193 [TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337 [TBL] [Abstract][Full Text] [Related]
16. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K; Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123 [TBL] [Abstract][Full Text] [Related]
17. Recent FDA approvals and changes. AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092 [No Abstract] [Full Text] [Related]
18. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898 [TBL] [Abstract][Full Text] [Related]
19. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. Decloedt EH; Lesosky M; Maartens G; Joska JA AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772 [TBL] [Abstract][Full Text] [Related]
20. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA; Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]